Your Client Rank:
Loading...
99
Updated 01-May-2025
| Company | Sales | Gross M. | SGA % Sales | R&D % Sales | Trading M. | Tax Rate | Net Income | EPS |
| | | | | | | | |
| Ascendis | 47.1% | -0.7% | -24.6% | -29.1% | | | | |
| Lilly | 17.9% | 0.3% | -6.2% | -10.2% | 9.4% | -1.2% | 30.0% | 30.5% |
| Novo | 12.9% | -0.2% | -2.2% | -2.3% | 1.2% | 0.8% | 14.5% | 15.5% |
| Daiichi | 10.9% | 1.5% | 2.5% | -3.6% | 4.6% | 4.0% | 14.0% | 14.1% |
| Vertex | 10.3% | 0.9% | -2.1% | -19.3% | 52.1% | -25.4% | >100% | >100% |
| Eisai | 8.4% | -1.3% | -2.4% | -6.7% | 10.6% | -1.5% | 19.0% | 20.3% |
| Sanofi | 6.6% | 0.9% | -3.4% | -3.2% | 5.1% | 0.8% | 10.6% | 11.2% |
| AbbVie | 6.4% | 0.3% | -3.8% | -7.5% | 4.7% | -1.0% | 12.7% | 12.8% |
| Regeneron | 6.1% | 0.2% | -1.6% | -0.6% | 2.5% | 4.9% | 7.5% | 8.1% |
| Astra | 6.1% | 0.5% | -1.5% | -0.8% | 3.6% | 0.8% | 10.8% | 10.7% |
| Chugai | 4.6% | 1.3% | -2.6% | -1.4% | 3.1% | -1.7% | 9.9% | 9.2% |
| Roche | 4.4% | 0.2% | -1.3% | -1.4% | 1.8% | 2.7% | 6.7% | 6.6% |
| JnJ | 4.0% | 0.0% | -1.0% | -3.3% | 2.9% | 0.5% | 5.8% | 6.8% |
| Teva | 3.3% | 1.6% | -6.7% | 0.0% | 2.7% | 2.4% | 8.8% | 7.8% |
| Novartis | 3.2% | 0.1% | -1.1% | 0.6% | 1.9% | 0.5% | 5.2% | 6.4% |
| Gilead | 3.0% | -0.2% | -1.8% | -10.7% | 9.8% | -5.6% | 16.5% | 16.9% |
| Amgen | 2.7% | -0.2% | -0.8% | 1.8% | -0.9% | 1.4% | 3.4% | 3.6% |
| Glaxo | 2.6% | 0.0% | 0.2% | 0.6% | 1.2% | 0.8% | 4.3% | 3.7% |
| Merck | 2.4% | 0.0% | -1.1% | -4.1% | 2.9% | 0.0% | 5.7% | 5.8% |
| Bayer | 1.5% | 1.6% | -2.0% | -1.2% | 16.9% | | 4.4% | 4.3% |
| Lundbeck | 1.0% | 0.1% | -0.8% | 3.4% | 0.8% | 6.9% | -0.2% | -3.3% |
| Takeda | 0.9% | 0.2% | -1.0% | 0.2% | 16.1% | -3.0% | 2.7% | 4.4% |
| Biogen | -0.7% | 0.4% | 0.1% | 0.5% | 1.5% | 1.9% | 1.2% | 1.0% |
| Shionogi | -0.9% | -1.1% | 2.0% | 0.7% | -5.1% | 3.3% | -5.2% | -4.2% |
| Pfizer | -2.7% | 0.0% | 0.3% | 2.7% | -1.1% | 0.6% | -3.8% | -4.1% |
| Astellas | -3.4% | -0.7% | -2.4% | 2.3% | 0.9% | -5.8% | -0.7% | -0.8% |
| Bristol | -4.7% | 0.4% | 1.1% | -14.2% | 28.6% | -20.9% | 38.0% | 38.7% |
| Neurocrine | | | | | | | | |
| EU Major | 5.4% | 0.6% | -1.9% | -1.2% | 3.7% | 0.8% | 8.7% | 8.3% |
| Other EU | 11.1% | 0.3% | -7.8% | -6.1% | 46.8% | -26.2% | >100% | |
| US Major | 4.3% | 0.4% | -2.2% | -6.7% | 6.2% | -2.2% | 11.4% | 17.3% |
| US Big Biotech | 4.0% | 0.2% | -1.8% | -6.6% | 5.8% | -2.5% | 12.2% | 11.3% |
| Other US | 3.3% | 1.6% | -6.7% | 0.0% | 2.7% | 2.4% | 8.8% | 7.8% |
| Japanese | 3.2% | 0.5% | 0.0% | -0.9% | 5.9% | -0.8% | 5.7% | 7.2% |
